Literature DB >> 10681415

Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.

C J Packard1, T Demant, J P Stewart, D Bedford, M J Caslake, G Schwertfeger, A Bedynek, J Shepherd, D Seidel.   

Abstract

Apolipoprotein B (apoB) metabolism was investigated in 20 men with plasma triglyceride 0.66-2.40 mmol/l and plasma cholesterol 3.95-6. 95 mmol/l. Kinetics of VLDL(1) (S(f) 60-400), VLDL(2) (S(f) 20-60), IDL (S(f) 12-20), and LDL (S(f) 0;-12) apoB were analyzed using a trideuterated leucine tracer and a multicompartmental model which allowed input into each fraction. VLDL(1) apoB production varied widely (from 5.4 to 26.6 mg/kg/d) as did VLDL(2) apoB production (from 0.18 to 8.4 mg/kg/d) but the two were not correlated. IDL plus LDL apoB direct production accounted for up to half of total apoB production and was inversely related to plasma triglyceride (r = -0.54, P = 0.009). Percent of direct apoB production into the IDL/LDL density range (r = 0.50, P < 0.02) was positively related to the LDL apoB fractional catabolic rate (FCR). Plasma triglyceride in these subjects was determined principally by VLDL(1) and VLDL(2) apoB fractional transfer rates (FTR), i.e., lipolysis. IDL apoB concentration was regulated mainly by the IDL to LDL FTR (r = -0.71, P < 0.0001). LDL apoB concentration correlated with VLDL(2) apoB production (r = 0.48, P = 0.018) and the LDL FCR (r = -0.77, P < 0. 001) but not with VLDL(1), IDL, or LDL apoB production. Subjects with predominantly small, dense LDL (pattern B) had lower VLDL(1) and VLDL(2) apoB FTRs, higher VLDL(2) apoB production, and a lower LDL apoB FCR than those with large LDL (pattern A). Thus, the metabolic conditions that favored appearance of small, dense LDL were diminished lipolysis of VLDL, resulting in a raised plasma triglyceride above the putative threshold of 1.5 mmol/l, and a prolonged residence time for LDL. This latter condition presumably permitted sufficient time for the processes of lipid exchange and lipolysis to generate small LDL particles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681415

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  53 in total

1.  Conway Memorial Lecture 2002. The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Oct-Dec       Impact factor: 1.568

2.  Inverse problems from biomedicine: inference of putative disease mechanisms and robust therapeutic strategies.

Authors:  James Lu; Elias August; Heinz Koeppl
Journal:  J Math Biol       Date:  2012-04-18       Impact factor: 2.259

Review 3.  Diabetes: mellitus or lipidus?

Authors:  E Shafrir; I Raz
Journal:  Diabetologia       Date:  2003-03-14       Impact factor: 10.122

4.  Effect of relative weight group change on nuclear magnetic resonance spectroscopy derived lipoprotein particle size and concentrations among adolescents.

Authors:  Russell Jago; Kimberly L Drews; James D Otvos; Gary D Foster; Marsha D Marcus; John B Buse; Michele Mietus-Snyder; Steven M Willi
Journal:  J Pediatr       Date:  2014-02-05       Impact factor: 4.406

5.  In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample.

Authors:  Martin Jansen; Peter Pfaffelhuber; Michael M Hoffmann; Gerhard Puetz; Karl Winkler
Journal:  J Lipid Res       Date:  2016-03-25       Impact factor: 5.922

6.  Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Frank M Sacks
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

Review 7.  Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.

Authors:  Davide Noto; Angelo B Cefalù; Maurizio R Averna
Journal:  Curr Atheroscler Rep       Date:  2014-06       Impact factor: 5.113

8.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

9.  Serum small dense low-density lipoprotein concentrations are elevated in patients with significant coronary artery stenosis and are related to features of the metabolic syndrome.

Authors:  Shima Yazdandoust; Seyyed Mohammad Reza Parizadeh; Mohsen Moohebati; Parichehreh Yaghmaei; Amir Ali Rahsepar; Shima Tavallaie; Mohammad Soukhtanloo; Roshanak Khojasteh; Roghayeh Paydar; Afsoon Fazlinezhad; Homa Falsoleiman; Mashalla Dehghani; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  Lipids       Date:  2012-08-18       Impact factor: 1.880

10.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.